Nov 12, 2020 / 03:15PM GMT
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst
Everyone, welcome to the last day of our healthcare conference at Crédit Suisse. My name is Tiago Fauth, mid-cap biotech analyst here at Crédit Suisse. And I'm joined today by the Immunovant team. They're going to do a presentation. Feel free to e-mail me any questions, and I'll try to work those in towards the end.
But for now, that's it, I think. Pete, you can take it away.
Peter Salzmann - Immunovant, Inc. - CEO & Director
Super. Thanks, Tiago. Let me just share my screen here. You see that, okay?
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst
Yes.
Peter Salzmann - Immunovant, Inc. - CEO & Director
Excellent. So I just want to briefly touch on our safe harbor presentation statement. This is on our website, this entire presentation is on our website, and I will be making some forward-looking
Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
